Patents by Inventor John E. Davies

John E. Davies has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190203145
    Abstract: A lubricating composition comprising an oil of lubricating viscosity, 1 to 1000 parts per million by weight of titanium in the form of an oil-soluble titanium-containing material, and at least one additional lubricant additive provides beneficial effects on properties such as deposit control, oxidation, and filterability in engine oils.
    Type: Application
    Filed: March 8, 2019
    Publication date: July 4, 2019
    Inventors: Mark C. Davies, Virginia A. Carrick, Jody A. Kocsis, Patrick E. Mosier, Matthew D. Gieselman, John D. Pudelski, Brent R. Dohner, Jonathan S. Vilardo
  • Publication number: 20190134101
    Abstract: The invention features compositions including genetically modified human umbilical cord perivascular cells (HUCPVCs), medium conditioned by HUCPVCs (e.g., genetically modified HUCPVCs), the soluble fraction of medium conditioned by HUCPVCs (e.g., genetically modified HUCPVCs), and pharmaceutical compositions thereof, and methods of use thereof for treatment of wounds.
    Type: Application
    Filed: June 15, 2017
    Publication date: May 9, 2019
    Inventors: Lorena Ruth Braid, John E. Davies
  • Publication number: 20190125804
    Abstract: Herein described is a method for treating cancer in a subject by administering a human umbilical cord perivascular cell (HUCPVC) that has been genetically modified to increase the expression of an oligonucleotide or a polypeptide such as an anti-cancer antibody.
    Type: Application
    Filed: June 14, 2017
    Publication date: May 2, 2019
    Inventors: Catalina Estrada Vallejo, John E. Davies
  • Publication number: 20170157180
    Abstract: Human progenitor cells are extracted from perivascular tissue of human umbilical cord. The progenitor cell population proliferates rapidly, and harbours osteogenic progenitor cells and MHC?/? progenitor cells, and is useful to grow and repair human tissues including bone.
    Type: Application
    Filed: February 23, 2017
    Publication date: June 8, 2017
    Applicants: Tissue Regeneration Therapeutics Inc., Tissue Regeneration Therapeutics Inc.
    Inventors: John E. DAVIES, Dolores BAKSH, Rahul SARUGASER, Morris HOSSEINI, Antony D.S. LICKORISH
  • Patent number: 9644182
    Abstract: Described is a method of expanding human progenitor cells by suspension culturing under non-static conditions. The culturing method provides a three-dimensional space for the rapid expansion of desirable progenitors. By this method, a new compartment of multipotential progenitor cells has been identified, which give rise under differentiation conditions to progeny including osteoblasts, chondrocytes, myoblasts, adipocytes, and other non-hematopoietic cell types. Their use in cell and tissue-based engineering is described.
    Type: Grant
    Filed: July 26, 2007
    Date of Patent: May 9, 2017
    Inventors: Dolores Baksh, John E. Davies, Peter Zandstra
  • Patent number: 9611456
    Abstract: Human progenitor cells are extracted from perivascular tissue of human umbilical cord. The progenitor cell population proliferates rapidly, and harbors osteogenic progenitor cells and MHC?/? progenitor cells, and is useful to grow and repair human tissues including bone.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: April 4, 2017
    Assignee: Tissue Regeneration Therapeutics Inc.
    Inventors: John E. Davies, Dolores Baksh, Rahul Sarugaser, Morris Hosseini, Antony D. S. Lickorish
  • Patent number: 9567564
    Abstract: Human progenitor cells are extracted from perivascular tissue of human umbilical cord. The progenitor cell population proliferates rapidly, and harbors osteogenic progenitor cells and MHC?/? progenitor cells, and is useful to grow and repair human tissues including bone.
    Type: Grant
    Filed: May 28, 2013
    Date of Patent: February 14, 2017
    Assignee: Tissue Regeneration Therapeutics Inc.
    Inventors: John E. Davies, Dolores Baksh, Rahul Sarugaser, Morris Hosseini, Antony D. S. Lickorish
  • Publication number: 20160032241
    Abstract: Human progenitor cells are extracted from perivascular tissue of human umbilical cord. The progenitor cell population proliferates rapidly, and harbours osteogenic progenitor cells and MHC?/? progenitor cells, and is useful to grow and repair human tissues including bone.
    Type: Application
    Filed: October 15, 2015
    Publication date: February 4, 2016
    Inventors: John E. DAVIES, Dolores BAKSH, Rahul SARUGASER, Morris HOSSEINI, Antony D.S. LICKORISH
  • Publication number: 20150246079
    Abstract: Described herein is a method for modulating an immune reaction between lymphocytes and a body recognized by the lymphocytes as foreign. The method exploits the immunomodulating activity of a new class of progenitor cells termed HUCPVCs derived from the perivascular region of human umbilical cord. The method can also employ soluble factors exuded by cultured HUCPVCs. The method is useful to treat immune disorders including graft versus host disease, autoimmune disorders, and the like.
    Type: Application
    Filed: November 26, 2014
    Publication date: September 3, 2015
    Inventors: John E. DAVIES, Jane E. ENNIS, Alejandro GOMEZ-ARISTIZABAL, Dolores BAKSH
  • Patent number: 8900573
    Abstract: Described herein is a method for modulating an immune reaction between lymphocytes and a body recognized by the lymphocytes as foreign. The method exploits the immunomodulating activity of a new class of progenitor cells termed HUCPVCs derived from the perivascular region of human umbilical cord. The method can also emply soluble factors exuded by cultured HUCPVCs. The method is useful to treat immune disorders including graft versus host disease, autoimmune disorders, and the like.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: December 2, 2014
    Inventors: John E. Davies, Jane Ennis, Alejandro Gomez-Aristiz-Abal, Dolores Baksh
  • Patent number: 8790923
    Abstract: Viable progenitor cells are extracted from frozen umbilical cord tissue. In embodiments, the umbilical cord tissue is a blood vessel bearing perivascular Wharton's jelly, and the extracted progenitor cells are HUCPVCs.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: July 29, 2014
    Inventors: Jane E. Ennis, Rahul Sarugaser, John E. Davies
  • Publication number: 20130259840
    Abstract: Human progenitor cells are extracted from perivascular tissue of human umbilical cord. The progenitor cell population proliferates rapidly, and harbours osteogenic progenitor cells and MHC?/? progenitor cells, and is useful to grow and repair human tissues including bone.
    Type: Application
    Filed: May 28, 2013
    Publication date: October 3, 2013
    Applicant: Tissue Regeneration Therapeutics Inc.
    Inventors: John E. Davies, Dolores Baksh, Rahul Sarugaser, Morris Hosseini, Antony D.S. Lickorish
  • Patent number: 8481311
    Abstract: Human progenitor cells are extracted from perivascular tissue of human umbilical cord. The progenitor cell population proliferates rapidly, and harbors osteogenic progenitor cells and MHC?/? progenitor cells, and is useful to grow and repair human tissues including bone.
    Type: Grant
    Filed: June 11, 2009
    Date of Patent: July 9, 2013
    Assignee: Tissue Regeneration Therapeutics Inc.
    Inventors: John E. Davies, Dolores Baksh, Rahul Sarugaser, Morris Hosseini, Antony D. S. Lickorish
  • Publication number: 20130089565
    Abstract: Described herein is a method for modulating an immune reaction between lymphocytes and a body recognized by the lymphocytes as foreign. The method exploits the immunomodulating activity of a new class of progenitor cells termed HUCPVCs derived from the perivascular region of human umbilical cord. The method can also emply soluble factors exuded by cultured HUCPVCs. The method is useful to treat immune disorders including graft versus host disease, autoimmune disorders, and the like.
    Type: Application
    Filed: September 28, 2012
    Publication date: April 11, 2013
    Inventors: John E. Davies, Jane Ennis, Alejandro Gomez-Aristiz-Abal, Dolores Baksh
  • Publication number: 20130023049
    Abstract: Viable progenitor cells are extracted from frozen umbilical cord tissue. In embodiments, the umbilical cord tissue is a blood vessel bearing perivascular Wharton's jelly, and the extracted progenitor cells are HUCPVCs.
    Type: Application
    Filed: September 28, 2012
    Publication date: January 24, 2013
    Inventors: Jane E. ENNIS, Rahul SARUGASER, John E. DAVIES
  • Publication number: 20120270031
    Abstract: The present invention relates to a method of coating a porous material such as a medical implant with a layer of calcium phosphate, wherein the material is submersed in an aqueous solution of calcium, phosphate and carbonate ions, and the pH of the solution is gradually increased. A calcium phosphate coating is formed on an internal surface of the porous material by agitating the solution during coating formation.
    Type: Application
    Filed: September 28, 2010
    Publication date: October 25, 2012
    Applicant: REGENERATION THERAPEUTIC INC.
    Inventors: Limin Guan, John E. Davies
  • Patent number: 8278102
    Abstract: Viable progenitor cells are extracted from frozen umbilical cord tissue. In embodiments, the umbilical cord tissue is a blood vessel bearing perivascular Wharton's jelly, and the extracted progenitor cells are HUCPVCs.
    Type: Grant
    Filed: December 21, 2006
    Date of Patent: October 2, 2012
    Inventors: Jane Ennis, Rahul Sarugaser, John E. Davies
  • Patent number: 8277794
    Abstract: Described herein is a method for modulating an immune reaction between lymphocytes and a body recognized by the lymphocytes as foreign. The method exploits the immunomodulating activity of a new class of progenitor cells termed HUCPVCs derived from the perivascular region of human umbilical cord. The method can also employ soluble factors exuded by cultured HUCPVCs. The method is useful to treat immune disorders including graft versus host disease, autoimmune disorders, and the like.
    Type: Grant
    Filed: May 4, 2007
    Date of Patent: October 2, 2012
    Inventors: John E. Davies, Jane Ennis, Alejandro Gomez-Aristiz-Abal, Dolores Baksh
  • Publication number: 20110076396
    Abstract: The present invention relates to a method of coating a porous material such as a medical implant with a layer of calcium phosphate, wherein the material is submersed in an aqueous solution of calcium, phosphate and carbonate ions, and the pH of the solution is gradually increased. A calcium phosphate coating is formed on an internal surface of the porous material by agitating the solution during coating formation.
    Type: Application
    Filed: September 28, 2009
    Publication date: March 31, 2011
    Inventors: Limin Guan, John E. Davies
  • Publication number: 20090285842
    Abstract: Described herein is a method for modulating an immune reaction between lymphocytes and a body recognized by the lymphocytes as foreign. The method exploits the immunomodulating activity of a new class of progenitor cells termed HUCPVCs derived from the perivascular region of human umbilical cord. The method can also employ soluble factors exuded by cultured HUCPVCs. The method is useful to treat immune disorders including graft versus host disease, autoimmune disorders, and the like.
    Type: Application
    Filed: May 4, 2007
    Publication date: November 19, 2009
    Inventors: John E. Davies, Jane Ennis, Alejandro Gomez-Aristiz-Abal, Dolores Baksh